[go: up one dir, main page]
Wikipedia

CD30

CD30, also known as TNFRSF8 (TNF receptor superfamily member 8),[5] is a cell membrane protein of the tumor necrosis factor receptor family and a tumor marker.

TNFRSF8
Available structures
PDBOrtholog search: PDBe RCSB
Identifiers
AliasesTNFRSF8, CD30, D1S166E, Ki-1, tumor necrosis factor receptor superfamily member 8, TNF receptor superfamily member 8
External IDsOMIM: 153243; MGI: 99908; HomoloGene: 949; GeneCards: TNFRSF8; OMA:TNFRSF8 - orthologs
Orthologs
SpeciesHumanMouse
Entrez

943

21941

Ensembl

ENSG00000120949

ENSMUSG00000028602

UniProt

P28908

Q60846

RefSeq (mRNA)

NM_001243
NM_001281430
NM_152942

NM_009401

RefSeq (protein)

NP_001234
NP_001268359

NP_033427

Location (UCSC)Chr 1: 12.06 – 12.14 MbChr 4: 144.99 – 145.04 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

Function

edit

This receptor is expressed by activated, but not by resting, T and B cells. TRAF2 and TRAF5 can interact with this receptor, and mediate the signal transduction that leads to the activation of NF-kappaB.[6] It is a positive regulator of apoptosis,[7] and also has been shown to limit the proliferative potential of autoreactive CD8 effector T cells and protect the body against autoimmunity.[citation needed] Two alternatively spliced transcript variants of this gene encoding distinct isoforms have been reported.[5]

Clinical significance

edit

CD30 is associated with anaplastic large cell lymphoma. It is expressed in embryonal carcinoma but not in seminoma and is thus a useful marker in distinguishing between these germ cell tumors.[8] CD30 and CD15 are also expressed on Reed-Sternberg cells typical for Hodgkin's lymphoma.[9]

Cancer treatment

edit

CD30 is the target of the FDA approved therapeutic brentuximab vedotin (Adcetris). It is approved for use in:

  1. Hodgkin lymphoma (HL) (brentuximab vedotin) after failure of autologous stem cell transplant (ASCT)
  2. HL in patients who are not ASCT candidates after failure of at least 2 multiagent chemotherapy regimens
  3. Systemic anaplastic large cell lymphoma (sALCL) after failure of at least 1 multiagent chemotherapy regimen[10]
  4. Primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy[11]
  5. Various types of CD30-positive T cell lymphomas[12]

Brentuximab vedotin is also currently being studied in and recommended for treating:

  1. Various types of CD30-positive B cell lymphomas[13]
  2. CD30-positive cases of the NK cell lymphoma, extranodal NK/T-cell lymphoma, nasal type[14]

Interactions

edit

CD30 has been shown to interact with TRAF5,[6] and TRAF2.[6][7]

References

edit
  1. ^ a b c GRCh38: Ensembl release 89: ENSG00000120949 – Ensembl, May 2017
  2. ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000028602 – Ensembl, May 2017
  3. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. ^ a b "Entrez Gene: TNFRSF8 tumor necrosis factor receptor superfamily member 8". National Library of Medicine, National Center for Biotechnology Information. 22 September 2022. Retrieved 6 November 2022.
  6. ^ a b c Aizawa S, Nakano H, Ishida T, Horie R, Nagai M, Ito K, et al. (January 1997). "Tumor necrosis factor receptor-associated factor (TRAF) 5 and TRAF2 are involved in CD30-mediated NFkappaB activation". The Journal of Biological Chemistry. 272 (4): 2042–2045. doi:10.1074/jbc.272.4.2042. PMID 8999898.
  7. ^ a b Duckett CS, Thompson CB (November 1997). "CD30-dependent degradation of TRAF2: implications for negative regulation of TRAF signaling and the control of cell survival". Genes & Development. 11 (21): 2810–2821. doi:10.1101/gad.11.21.2810. PMC 316646. PMID 9353251.
  8. ^ Teng LH, Lu DH, Xu QZ, Fu YJ, Yang H, He ZL (Nov 2005). "[Expression and diagnostic significance of OCT4, CD117 and CD30 in germ cell tumors]". Zhonghua Bing Li Xue Za Zhi Chinese Journal of Pathology (in Chinese). 34 (11): 711–5. PMID 16536313.
  9. ^ Gorczyca W, Tsang P, Liu Z, Wu CD, Dong HY, Goldstein M, Cohen P, Gangi M, Weisberger J (Feb 2003). "CD30-positive T-cell lymphomas co-expressing CD15: an immunohistochemical analysis". International Journal of Oncology. 22 (2): 319–24. doi:10.3892/ijo.22.2.319. PMID 12527929.
  10. ^ Deng C, Pan B, O'Connor OA (Jan 2013). "Brentuximab vedotin". Clinical Cancer Research. 19 (1): 22–7. doi:10.1158/1078-0432.CCR-12-0290. PMID 23155186.
  11. ^ "FDA approves Brentuximab vedotin for the treatment of adult patients with primary cutaneous anaplastic large cell lymphoma". FDA.gov. Retrieved March 2, 2018.
  12. ^ "FDA approves first-line treatment for peripheral T-cell lymphoma under new review pilot". FDA.gov. 24 March 2020. Retrieved December 13, 2023.
  13. ^ Berger GK, McBride A, Lawson S, Royball K, Yun S, Gee K, Bin Riaz I, Saleh AA, Puvvada S, Anwer F (January 2017). "Brentuximab vedotin for treatment of non-Hodgkin lymphomas: A systematic review". Critical Reviews in Oncology/Hematology. 109: 42–50. doi:10.1016/j.critrevonc.2016.11.009. PMC 5218629. PMID 28010897.
  14. ^ Hu B, Oki Y (2018). "Novel Immunotherapy Options for Extranodal NK/T-Cell Lymphoma". Frontiers in Oncology. 8: 139. doi:10.3389/fonc.2018.00139. PMC 5937056. PMID 29761078.

Further reading

edit
edit

This article incorporates text from the United States National Library of Medicine, which is in the public domain.


Retrieved from "https://en.wikipedia.org/w/index.php?title=CD30&oldid=1251265304"